1887

Abstract

Tedizolid, a second-generation oxazolidinone that displays a potent activity against Gram-positive pathogens, could be an interesting option for the treatment of bone and joint infections (BJIs). The aim of the study was to determine minimal inhibitory concentration (MIC) of tedizolid against a collection of 359 clinical isolates involved in clinically-documented BJIs and to compare them to those of comparator agents used in Gram-positive infections. Of the 104  and 102 coagulase-negative staphylococci (CoNS) isolates, 99 and 92 % were categorized as susceptible to tedizolid, respectively (MIC=0.12/0.25 µg ml and MIC=0.25/0.5 µg ml), regardless of their methicillin resistance. MIC and MIC for the 51 enterococci, the 50 spp. and the 52 spp. were either equal or inferior to 0.5 µg ml. Altogether, tedizolid possessed a potent activity against most of the BJI Gram-positive pathogens with 95 % of them exhibiting a MIC ≤0.5 µg ml.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000595
2017-10-01
2020-01-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/10/1374.html?itemId=/content/journal/jmm/10.1099/jmm.0.000595&mimeType=html&fmt=ahah

References

  1. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004;53:928–935 [CrossRef][PubMed]
    [Google Scholar]
  2. Mears SC, Edwards PK. Bone and joint infections in older adults. Clin Geriatr Med 2016;32:555–570 [CrossRef][PubMed]
    [Google Scholar]
  3. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev 2014;27:302–345 [CrossRef][PubMed]
    [Google Scholar]
  4. Perez-Jorge C, Gomez-Barrena E, Horcajada JP, Puig-Verdie L, Esteban J. Drug treatments for prosthetic joint infections in the era of multidrug resistance. Expert Opin Pharmacother 2016;17:1233–1246 [CrossRef][PubMed]
    [Google Scholar]
  5. Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 2015;61:1315–1321 [CrossRef][PubMed]
    [Google Scholar]
  6. Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 2015;75:253–270 [CrossRef][PubMed]
    [Google Scholar]
  7. Silva-del Toro SL, Greenwood-Quaintance KE, Patel R. In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci. Diagn Microbiol Infect Dis 2016;85:102–104 [CrossRef][PubMed]
    [Google Scholar]
  8. Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother 2016;71:152–155 [CrossRef][PubMed]
    [Google Scholar]
  9. Bensaci M, Sahm D. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe. Diagn Microbiol Infect Dis 2017;87:133–138 [CrossRef][PubMed]
    [Google Scholar]
  10. Bassetti M, Righi E. Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opin Drug Saf 2016;15:467–481 [CrossRef][PubMed]
    [Google Scholar]
  11. Yuste JR, Bertó J, del Pozo JL, Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J Antimicrob Chemother 2017;72:625–628 [CrossRef][PubMed]
    [Google Scholar]
  12. Khatchatourian L, Le Bourgeois A, Asseray N, Biron C, Lefebvre M et al. Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments. J Antimicrob Chemother 2017;72:2135–2136 [CrossRef][PubMed]
    [Google Scholar]
  13. Park KH, Greenwood-Quaintance KE, Mandrekar J, Patel R. Activity of tedizolid in methicillin-resistant Staphylococcus aureus experimental foreign body-associated osteomyelitis. Antimicrob Agents Chemother 2016;60:6568–6572 [CrossRef][PubMed]
    [Google Scholar]
  14. Park KH, Greenwood-Quaintance KE, Schuetz AN, Mandrekar JN, Patel R. Activity of tedizolid in methicillin-resistant Staphylococcus epidermidis experimental foreign body-associated osteomyelitis. Antimicrob Agents Chemother 2017;61:e01644-16 [CrossRef][PubMed]
    [Google Scholar]
  15. Si S, Durkin MJ, Mercier MM, Yarbrough ML, Liang SY. Successful treatment of prosthetic joint infection due to vancomycin-resistant enterococci with tedizolid. Infect Dis Clin Pract 2017;25:105–107 [CrossRef][PubMed]
    [Google Scholar]
  16. Schmidt-Malan SM, Greenwood Quaintance KE, Karau MJ, Patel R. In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis 2016;85:77–79 [CrossRef][PubMed]
    [Google Scholar]
  17. Littorin C, Hellmark B, Nilsdotter-Augustinsson Å, Söderquist B. In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections. Eur J Clin Microbiol Infect Dis 2017;36:1549–1552 [CrossRef][PubMed]
    [Google Scholar]
  18. Grammatico-Guillon L, Baron S, Gettner S, Lecuyer AI, Gaborit C et al. Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes. J Hosp Infect 2012;82:40–48 [CrossRef][PubMed]
    [Google Scholar]
  19. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013;56:e1–e25. [CrossRef][PubMed]
    [Google Scholar]
  20. Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 2014;58:6462–6470 [CrossRef][PubMed]
    [Google Scholar]
  21. Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014;42:1275–1284 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000595
Loading
/content/journal/jmm/10.1099/jmm.0.000595
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error